Assess whether biosimilarity is analytically justified (a87920)

Situation

An RWE group proposing a post-marketing study instead of a new RCT cannot treat a boxed-warning proposal from the review division as color commentary on CMC comparability package for a site change. Labeling negotiator must close biosimilarity is analytically justified from that extract under Pharma & Life Sciences / Clinical and Evidence Strategy.

Decision

Labeling negotiator in an RWE group proposing a post-marketing study instead of a new RCT must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using CMC comparability package for a site change after a boxed-warning proposal from the review division.

Hypotheses to test

• A boxed-warning proposal from the review division is noise around an already-controlled Clinical and Evidence Strategy process in an RWE group proposing a post-marketing study instead of a new RCT, given CMC comparability package for a site change.
• A boxed-warning proposal from the review division is the event in CMC comparability package for a site change that forces Proceed under protocol for labeling negotiator under Pharma & Life Sciences.
• CMC comparability package for a site change shows a one-file miss after a boxed-warning proposal from the review division, not a Clinical and Evidence Strategy program failure.
• CMC comparability package for a site change cannot decide biosimilarity is analytically justified yet after a boxed-warning proposal from the review division; hold is the only Pharma & Life Sciences close an RWE group proposing a post-marketing study instead of a new RCT can defend.

Analysis required

• Trace CMC, labeling, or pharmacovigilance facts in CMC comparability package for a site change after a boxed-warning proposal from the review division.
• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on biosimilarity is analytically justified.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read CMC comparability package for a site change against a boxed-warning proposal from the review division and write the one fact that would move biosimilarity is analytically justified for labeling negotiator.

Recommendation